CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated withFLT3 internal tandem duplication
- 1 April 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (7) , 2770-2774
- https://doi.org/10.1182/blood-2002-01-0228
Abstract
The etiology of acute myeloid leukemia (AML) is largely unknown. Biologic and epidemiologic data implicate exogenous toxicants, including cytotoxic drugs, benzene, radiation, and cigarette smoking. Allelic variation in genes encoding enzymes such as NADP(H) quinone oxidoreductase (NQO1) and glutathione S-transferase T1 (GSTT1) that metabolize environmental toxicants predispose to subtypes of AML, including therapy-related AML. We assayed NRAS oncogene mutation and FLT3 internal tandem duplication in 447 AML patients with an abnormal karyotype treated in Medical Research Council (MRC) AML clinical trials. Functional allelic variant frequencies in genes encoding carcinogen-metabolizing enzymesGSTT1, GSTM1, CYP1A1,CYP2D6, CYP2C19, SULT1A1, and NQO1 were previously determined for this cohort. FLT3 internal tandem duplication (ITD) frequency was 17%, and NRAS mutation 12% for the entire cohort. The 2 mutations were found together in only 4 patients. No association was found between enzyme allelic variant frequencies and the presence of FLT3 ITD for the entire cohort or within cytogenetic subgroups. CYP1A1*2B (Val) high-inducibility variant allele was overrepresented in patients with NRAS mutation compared with no mutation, for (1) the entire AML cohort (n = 8/53 vs 26/371; odds ratio [OR] = 2.36; 95% confidence interval [CI] 1.01-5.53) and (2) the poor-risk karyotype group (n = 6/14 vs 4/89; OR = 15.94; 95% CI 3.71-68.52) comprising patients with partial/complete deletion of chromosome 5 or 7, or abnormalities of chromosome 3. The CYP1A1*2B allele may predispose to the development of these subgroups of AML by augmented phase 1 metabolism to highly reactive intermediates of CYP1A1 substrates, including polycyclic aromatic hydrocarbons, or by generation of oxidative stress as a metabolic by-product.Keywords
This publication has 27 references indexed in Scilit:
- Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemiaBlood, 2002
- The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trialsBlood, 2001
- Smoking and acute myeloid leukemia: associations with morphology and karyotypic patterns and evaluation of dose–response relationsLeukemia Research, 2001
- Karyotype and age in acute myeloid leukemia.: Are they linked?Cancer Genetics and Cytogenetics, 2001
- INDUCTION OF CYTOCHROME P4501A1Annual Review of Pharmacology and Toxicology, 1999
- A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database.Environmental Health Perspectives, 1998
- Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage.Proceedings of the National Academy of Sciences, 1996
- The Relationship between Aryl Hydrocarbon Hydroxylase and Polymorphisms of the CYP1A1 GeneJapanese Journal of Cancer Research, 1996
- Functional significance of different human CYPlAl genotypesCarcinogenesis: Integrative Cancer Research, 1994
- DNA sequencing with chain-terminating inhibitorsProceedings of the National Academy of Sciences, 1977